433 related articles for article (PubMed ID: 20956992)
1. Iron supplementation to treat anemia in patients with chronic kidney disease.
Besarab A; Coyne DW
Nat Rev Nephrol; 2010 Dec; 6(12):699-710. PubMed ID: 20956992
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Anemia in chronic kidney disease: new advances.
Patel TV; Singh AK
Heart Fail Clin; 2010 Jul; 6(3):347-57. PubMed ID: 20630409
[TBL] [Abstract][Full Text] [Related]
4. New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
Vaziri ND; Kalantar-Zadeh K; Wish JB
Am J Kidney Dis; 2016 Mar; 67(3):367-75. PubMed ID: 26616335
[TBL] [Abstract][Full Text] [Related]
5. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
[TBL] [Abstract][Full Text] [Related]
6. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?
Nakanishi T; Kuragano T; Kaibe S; Nagasawa Y; Hasuike Y
Clin Exp Nephrol; 2012 Dec; 16(6):819-26. PubMed ID: 23053592
[TBL] [Abstract][Full Text] [Related]
7. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
Grabe DW
Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
[TBL] [Abstract][Full Text] [Related]
8. [Anemia and iron deficiency - treatment options in chronic kidney disease and in chronic heart failure].
Emrich IE; Böhm M; Heine GH
Dtsch Med Wochenschr; 2020 Dec; 145(24):1775-1780. PubMed ID: 33254253
[TBL] [Abstract][Full Text] [Related]
9. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.
Ueda N; Takasawa K
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30150549
[TBL] [Abstract][Full Text] [Related]
10. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.
Tessitore N; Girelli D; Campostrini N; Bedogna V; Pietro Solero G; Castagna A; Melilli E; Mantovani W; De Matteis G; Olivieri O; Poli A; Lupo A
Nephrol Dial Transplant; 2010 Dec; 25(12):3996-4002. PubMed ID: 20538788
[TBL] [Abstract][Full Text] [Related]
11. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
13. Hepcidin: clinical utility as a diagnostic tool and therapeutic target.
Coyne DW
Kidney Int; 2011 Aug; 80(3):240-4. PubMed ID: 21677632
[TBL] [Abstract][Full Text] [Related]
14. Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients.
Belo L; Rocha S; Valente MJ; Coimbra S; Catarino C; Bronze-da-Rocha E; Rocha-Pereira P; do Sameiro-Faria M; Oliveira JG; Madureira J; Fernandes JC; Miranda V; Santos-Silva A
Ren Fail; 2019 Nov; 41(1):662-672. PubMed ID: 31296086
[No Abstract] [Full Text] [Related]
15. [Evaluation of serum iron as a predictor of a hemoglobin response to injectable iron treatment in chronic hemodialysis patients].
Grèze C; Garrouste C; Pereira B; Hadj-Abdelkader M; Heng AÉ; Aniort J
Nephrol Ther; 2022 Dec; 18(7):634-642. PubMed ID: 36216731
[TBL] [Abstract][Full Text] [Related]
16. Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders.
Takasawa K; Takaeda C; Wada T; Ueda N
Nutrients; 2018 Mar; 10(4):. PubMed ID: 29596361
[No Abstract] [Full Text] [Related]
17. Intravenous iron supplementation in end-stage renal disease patients.
Matzke GR
Am J Kidney Dis; 1999 Mar; 33(3):595-7. PubMed ID: 10070926
[No Abstract] [Full Text] [Related]
18. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
Deira J; González-Sanchidrián S; Polanco S; Cebrián C; Jiménez M; Marín J; Gómez-Martino JR; Fernández-Pereira L; Tabernero J
Ren Fail; 2016 Aug; 38(7):1076-81. PubMed ID: 27197731
[TBL] [Abstract][Full Text] [Related]
19. Effect of aggressively driven intravenous iron therapy on infectious complications in end-stage renal disease patients on maintenance hemodialysis.
Bansal A; Sandhu G; Gupta I; Kalahalli S; Nayak R; Zouain E; Chitale RA; Meisels I; Chan G
Am J Ther; 2014; 21(4):250-3. PubMed ID: 22832501
[TBL] [Abstract][Full Text] [Related]
20. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
Frankenfield DL; Johnson CA
Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
